Corcept Therapeutics CORT EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's EBITDA?
- Corcept Therapeutics (CORT) reported EBITDA of -$49M in Q1 2026.
- How has Corcept Therapeutics's EBITDA changed year-over-year?
- Corcept Therapeutics's EBITDA decreased by 1363.6% year-over-year, from $3.88M to -$49M.
- What is the long-term trend for Corcept Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Corcept Therapeutics's EBITDA has grown at a -22.5% compound annual growth rate (CAGR), from $127.51M to $45.95M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.